Metoclopramide Gets Boxed Warning, REMS, For Movement Disorder Risk
Executive Summary
FDA issued a class-wide requirement Feb. 26 for metoclopramide-containing products to gain a boxed warning and Risk Evaluation and Mitigation Strategy to address the gastrointestinal drug's associated risk of tardive dyskinesia
You may also be interested in...
MiraLAX Targeted In Petition To FDA, But Physicians Back Pediatric Use
A consumer group petitions FDA for a black box warning on Merck’s MiraLAX and generic equivalents, citing the potential for adverse reactions in children. Gastroenterologists largely have not seen such risks from off-label pediatric use of the OTC laxative.
MiraLAX Targeted In Petition To FDA, But Physicians Back Pediatric Use
A consumer group petitions FDA for a black box warning on Merck’s MiraLAX and generic equivalents, citing the potential for adverse reactions in children. Gastroenterologists largely have not seen such risks from off-label pediatric use of the OTC laxative.
Salix Will Need To Dissolve Metozolv ODT Convenience Claims With Corrective Advertising Campaign; FDA Warning Letter Silent On REMS
An effort by Salix Pharmaceuticals to tout advantages for its orally disintegrating metoclopramide product Metozolv ODT has ended with a need to run a corrective advertising campaign